[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Authors
Keywords
-
Journal
LANCET
Volume 397, Issue 10276, Pages 797-804
Publisher
Elsevier BV
Online
2021-02-11
DOI
10.1016/s0140-6736(21)00237-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- (2020) Silke Gillessen et al. EUROPEAN UROLOGY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
- (2019) Michael S. Hofman et al. BJU INTERNATIONAL
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Accuracy of Dose Calibrators for68Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment
- (2018) Dale L. Bailey et al. JOURNAL OF NUCLEAR MEDICINE
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Results of a prospective phase 2 pilot trial of Lu177 PSMA 617 therapy for metastatic castrate resistant prostate cancer including Imaging predictors of treatment response and patterns of progression.
- (2018) Louise Emmett et al. Clinical Genitourinary Cancer
- Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
- (2018) Matthias M. Heck et al. EUROPEAN UROLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
- (2016) K. Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- WIDEN: A tool for medical image management in multicenter clinical trials
- (2014) Stéphane Chauvie et al. Clinical Trials
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now